|Status||Country of risk||Maturity (option)|
This field shows outstanding face value amount for outstanding bonds
|Issue ratings (M/S&P/F)|
|outstanding||Israel||**/**/**** (**/**/****)||2,200,000 EUR||***/***/***|
The cost of your order is $50
Enter your e-mail (for getting the document)
Please find user agreement here
|Borrower||Teva Pharmaceutical Industries|
|SPV / Issuer||Teva Pharmaceutical Finance Netherlands II|
|Bond type||Coupon bonds|
|Placement method||Open subscription|
We expect that the net proceeds to us from this offering and the concurrent offering, after deducting the Initial Purchasers’ discounts and estimated offering expenses payable by us, will be approximately $4,465 million. We expect to use the net proceeds of this offering, together with the net proceeds from the concurrent offering, to repay outstanding indebtedness, including indebtedness under the Term Loan Credit Agreement, dated as of November 16, 2015 (the “USD Term Loan Credit Agreement”), the Senior Unsecured Fixed Rate Japanese Yen Term Loan Credit Agreement, dated as of March 28, 2012 (the “JPY 2012 Credit Agreement”), the Senior Unsecured Japanese Yen Term Loan Credit Agreement, dated as of December 17, 2013 (the “JPY 2013 Credit Agreement”) and the Senior Unsecured Japanese Yen Term Loan Credit Agreement, dated as of March 22, 2017 (the “JPY 2017 Credit Agreement” and, collectively with the USD Term Loan Credit Agreement, the JPY 2012 Credit Agreement and the JPY 2013 Credit Agreement, in each case, as amended, the “Term Loan Credit Agreements”), the 1.40% USD Senior Notes due 2018 and the 2.875% EUR Senior Notes due 2019 with the remainder of the net proceeds to be used to pay related fees and expenses and/or otherwise for general corporate purposes.
|Par amount, integral multiple||1,000 EUR|
|Nominal of international bonds||1,000 EUR|
|Minimum settlement amount||100,000 EUR|
|Outstanding principal amount||100,000 EUR|
|Amount Outstanding||2,200,000 EUR|
|Outstanding face value amount||2,200,000 EUR|
|Exchanged into||Teva Pharmaceutical Industries, 4.5% 1mar2025, EUR|
|Other tranches||Teva Pharmaceutical Industries, 3.25% 15apr2022, EUR|
|Current coupon rate||4.5%|
|Day count fraction||***|
|Coupon frequency||2 time(s) per year|
|Interest accrual date||**/**/****|
|Trading floor||Date and time||Bid/ ask price (Yield)|
Indicative price (Yield) i
Indicative price is used to calculate the effective yield, duration, modified duration and is calculated according to the following priority of prices: weighted average price (Average), market price (Market), closing price (Close), admitted price (Admitted), middle price (Mid), last price (Last). Indicative yield is calculated according to the following priority of yields: yield to maturity (effective), yield to put/call (effective), current yield.
T-spread, bp i
T-spread is calculated as the difference between the issue yield and the yield on government securities of the USA, Great Britain and Germany in the corresponding issue currency and with comparable modified duration (the calculations are based on the effective yields only). The value is computed only for issues in USD, EUR, GBP.
Indicative bond and international bond quotes by Cbonds are calculated based on the methodology described here http://ru.cbonds.com/organizations/docdownload/8715.
The end result of the methodology is a single end-of-day Cbonds quote, which is based on bid and ask data of various trading floors and contributors working with this asset.
Quotes are published both anonymously and publicly in the section Bond Quotes by Market Participants: http://cbonds.com/quotes/market/. These quotes are indicative only. Organizations posting the quotes have no obligations to conduct transactions at these prices. To learn the actual current prices, you need to contact the respective organization. Trading floor quotes are available at http://cbonds.com/quotes/.
|01/22/2020||*** / *** (*** / ***)||*** (***)||***||***||Archive|
|Market participant||Date and time||Bid/ask or last price|
|Adamant Capital Partners||01/23/2020 13:27||***.** / ***.** (*.** / *.**)|
|Supranational bond issues|
|ISIN / ISIN RegS||XS1789456024|
|Common Code / Common Code RegS||178945602|
|Common Code 144A||178945947|
|CFI / CFI RegS||DBFUFR|
|FIGI / FIGI RegS||BBG00K6R14Q1|
|WKN / WKN RegS||A19XUC|
|Ticker||TEVA 4.5 03/01/25 REGS|
|Issuer rating on issue date (M/S&P/F)||***/***/***|
|Initial issue price (yield)||***% (*.**%)|
|Bookrunner:||Barclays, BNP Paribas, Citigroup, Credit Suisse, HSBC, Bank of America Merrill Lynch|
|Depository:||Clearstream Banking S.A., Euroclear Bank|
|Paying agent:||BNY Mellon (London branch)|
|Issuer Legal Adviser (International law):||Kirkland & Ellis|